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Abstract
Background
Venous thromboembolism (VTE) is a major cause of morbidity and mortality in elderly
patients. Extracellular DNA is a pro-inflammatory and pro-thrombotic mediator in vitro
and in animal models. Levels of circulating extracellular DNA (ceDNA) are increased in
VTE patients, but the association of ceDNA with VTE extent and clinical outcome is
poorly understood.
Objectives
We analyzed the association of ceDNA with the extent of VTE, categorized as distal and
proximal deep vein thrombosis and pulmonary embolism, and with the clinical outcomes
VTE recurrence and mortality.
Methods
We quantified ceDNA by a fluorescent probe, as well as circulating nucleosomes and neu-
trophil extracellular traps (NETs) by ELISA in plasma from 611 patients aged 65 years
with acute VTE of a prospective cohort study (SWITCO65+).
Results
Levels of ceDNA and nucleosomes, but not NETs, correlated with VTE extent. Infectious
comorbidities independently increased ceDNA levels in VTE. CeDNA strongly corre-
lated with C-reactive protein and leukocytosis, suggesting an association of ceDNA with
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Conclusions
Our study suggests that ceDNA levels in VTE patients reflect the degree of inflammation
and may serve as a biomarker to stratify VTE patients at risk for mortality.
Introduction
Venous thromboembolism (VTE), the combined disease entity of deep vein thrombosis (DVT)
and pulmonary embolism (PE), is a major cause of morbidity and mortality [1]. The incidence
of VTE increases with age [2] and the majority of VTE patients are 65 years or older [3]. The
increasing age of the population in Western countries necessitates new strategies for the stratifi-
cation of patients at high risk for adverse outcomes of VTE.
Plasma contains circulating extracellular DNA (ceDNA) and levels of ceDNA increase in
inflammatory, cardiovascular, and thromboembolic diseases [4, 5]. In vitro and in vivo data
suggest an active role of ceDNA in inflammation and thrombosis. The complex of extracel-
lular DNA with histones and neutrophil-derived peptides stimulates inflammation via acti-
vation of pattern recognition receptors on immune cells [6, 7]. In addition, extracellular
DNA and histones contribute to blood clotting via activating coagulation factors and plate-
lets [8, 9]. In agreement with these findings, infusions of DNases reduce tissue inflamma-
tion and prevent thrombosis in murine models by degrading extracellular DNA [10, 11].
Potential sources of ceDNA are dead cells and neutrophils through the release of neutrophil
extracellular traps (NETs), which are characterized as DNA-fibers containing histones and
enzymes from neutrophil granules [12].
CeDNA levels are increased in VTE patients, when compared to healthy controls [4, 13,
14]. However, the association of ceDNA with the extent and outcome of VTE is poorly under-
stood. We quantified ceDNA as well as circulating nucleosomes and NETs in plasma from
patients with acute VTE. Our data suggests that ceDNA in VTE patients reflects the magnitude
of inflammation and may serve as a biomarker to stratify VTE patients at risk for mortality.
Materials and methods
The Swiss venous thromboembolism cohort 65+
The Swiss Venous Thromboembolism Cohort 65+ (SWITCO65+) is a prospective multicenter
cohort study enrolling patients aged 65 years with acute, symptomatic VTE at nine Swiss
university and non-university hospitals from 2009 to 2013 [15, 16]. Patients with acute VTE
were identified in the inpatient and outpatient services of the study sites. Symptomatic DVT
was diagnosed as the acute onset of leg pain or swelling plus incomplete compressibility of a
venous segment on ultrasonography or an intraluminal filling defect on contrast venography
[17]. Because iliac veins and the inferior vena cava are technically difficult to compress, addi-
tional diagnostic criteria for the iliac and caval DVT included abnormal duplex flow patterns
compatible with thrombosis, an intraluminal filling defect on spiral computed tomography, or
magnetic resonance imaging venography [18, 19]. Patients with isolated distal DVT were only
eligible if the incompressible distal vein transverse diameter was at least 5 mm, because com-
pression ultrasonography has a lower diagnostic accuracy for distal DVT [20]. Symptomatic
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PE was diagnosed as the acute onset of dyspnea, chest pain, or syncope coupled with a new
high-probability ventilation/perfusion lung scan, a new contrast filling defect on the spiral co-
mputed tomography or pulmonary angiography, or a new documentation of a proximal DVT
either by ultrasound or venography. The ethics committees at each site approved the study
(Northwest/Central Switzerland, Bern, Geneva, Eastern Switzerland, Vaud, Zurich; see http://
www.swissethics.ch/eks.html for details). Eligible patients who had no exclusion criteria were
approached for informed consent to participate in the study.
Exclusion criteria
SWITCO65+ screened 1863 VTE patients (S1 Fig). Patients were excluded from the cohort
due to inability to provide consent (n = 285), no consent (n = 398), follow-up not possible
(n = 192), insufficient proficiency in German or French (n = 51), thrombosis at other sites
than the lower limb (n = 21), and catheter-related thrombosis (n = 7). Multiple reasons for
exclusion may apply. Patients with absent biosamples (n = 67), missing results from bio-
samples (n = 30), denying the use of data (n = 8), or withdrawing the informed consent
within one day from inclusion (n = 4) were excluded from our analysis. Our study focuses
on patients with a first VTE and we therefore excluded patients with prior VTE (n = 283).
Baseline characteristics
The collection of biosamples and patient data was performed as previously described [15, 16].
In brief, trained research nurses collected blood samples at the time of index VTE. Blood pro-
cessing was completed within 1 hour of collection. Data was recorded on standard data collec-
tion forms and included demographic information, comorbid conditions, medication history,
and laboratory data. Clinical and laboratory characteristics at baseline are summarized in
Table 1.
Adverse outcomes of VTE
Adverse outcomes of VTE were defined as previously published [16]. The primary medical
outcome was the recurrence of an objectively confirmed, symptomatic VTE, defined as a
fatal or new non-fatal PE or new DVT (proximal and/or distal) based on previously pub-
lished criteria [21, 22]. Additional adverse outcomes tested are the occurrence of all-cause,
PE-related or -unrelated, and cancer-related or -unrelated mortality. Death was PE-related
if PE was confirmed by autopsy, or if death followed a clinically severe PE, either initially
or after an objectively confirmed recurrent event. Death in a patient who died suddenly or
unexpectedly was classified as possibly PE-related. Unrelated deaths were classified as a
result of an obvious cause other than PE [23]. A committee of three blinded clinical experts
adjudicated all outcomes and classified the cause of all deaths as definitely due to PE, possi-
bly due to PE or due to other causes. Final classifications were made on the basis of the full
consensus of the committee.
Quantification of ceDNA
CeDNA in plasma was quantified with modifications as previously described [24]. In brief,
citrated plasma was diluted 20-fold in dilution buffer containing 0.1% BSA and 5 mM EDTA
in phosphate-buffered saline (PBS). Fifty microliters of diluted plasma was mixed with 50 μl of
PBS containing a fluorescent DNA-intercalating dye. DNA-fluorescence was then recorded in
a multi plate fluorometer (Fluoroskan; Thermo Fisher Scientific). Autofluorescence was con-
sidered background and determined in samples mixed with PBS without DNA dye. In initial
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experiments, we compared PicoGreen (1%; Life Technologies) and SytoxGreen (1 μM; Life
Technologies), two fluorescent DNA dyes commonly used for the quantification of extracellu-
lar DNA in plasma. While both dyes quantified DNA with a similar detection limit in saline,
SytoxGreen displayed a significantly higher sensitivity for DNA in plasma (S2 Fig). We there-
fore used SytoxGreen as a probe for ceDNA quantification.
Quantification of circulating nucleosomes
The quantification of circulating nucleosomes is based on a monoclonal antibody against
an epitope on the complex of DNA with histone H2A and H2B [12]. We coated microtiter
plates with 5 μg of this antibody. Plates were blocked with 2% bovine serum albumin (BSA,
Sigma-Aldrich) and 1% dry milk powder (Spinnrad) for 1 hour at 37˚C and washed once
Table 1. Characterization of VTE patients.
Analyzed VTE patients 611 (100%)
Demographic data
Age [years] (IQ-Range) 75 (69;81)
Females 278 (45%)
VTE extent
Distal DVT only 51 (8%)
Proximal DVT ± distal DVT 133 (22%)
PE ± DVT 427 (70%)
Medical history
Provoked index VTE 209 (34%)
Active cancer 127 (21%)
Severe infection/sepsis during the last 3 months 52 (9%)
Inflammatory bowel disease 18 (3%)
Acute rheumatic disease during the last 3 months 20 (3%)
Diabetes mellitus 97 (16%)
Arterial hypertension 388 (64%)
Chronic lung disease 80 (13%)
Chronic or acute heart failure 78 (13%)
History of major bleeding 63 (10%)
Anemia 257 (42%)
Renal failure (GFR < 30ml/min) 35 (6%)
Body mass index (IQ-range) 26.2 (24.0;29.7)
Medication
Concomitant antiplatelet therapy 194 (32%)
Initial vitamin K antagonist therapy 523 (86%)
Initial parenteral anticoagulation 590 (97%)
Laboratory parameters
Leukocytes [K/μl] (IQ-Range) 8.3 (6.5;11.1)
Platelets [K/μl] (IQ-Range) 213 (168;275)
us-CRP [mg/L] (IQ-Range) 24.4 (8.5;63.9)
D-dimer [ng/mL] (IQ-Range) 2517 (1634;3784)
Baseline characteristics of analyzed patients at index VTE. Medication indicates the type of therapy applied upon
diagnosis of acute VTE. Data presented as n (%) or median with interquartile (IQ)-range.
Missing values: Anemia (n = 33), Renal Failure (n = 43), BMI (n = 5), Leukocytes (n = 34), Platelets (n = 32), us-
CRP (n = 3), D-dimer (n = 21).
https://doi.org/10.1371/journal.pone.0191150.t001
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with PBS-Tween (PBS-T). Plasma samples, which were diluted 10-fold in PBS, were added
to wells and incubated for 30 minutes at 37˚C. Wells were then washed three times with
PBS-T. For detection of DNA, we added PBS containing 1% of Picogreen. Fluorescence was
then recorded with a multi plate fluorometer.
Quantification of circulating NETs
We quantified complexes of DNA, histones, and myeloperoxidase (MPO) as a marker of
NETs in plasma [25]. In brief, we coated microtiter plates with 1 μg of the anti-DNA-his-
tone H2A/H2B-complex antibody [12]. Plates were blocked with 2% BSA and 1% milk
powder for 1 hour at 37˚C. Plasma was diluted 20-fold in dilution buffer containing 2 mM
EDTA and 0.1% BSA in PBS. Diluted plasma was added to wells and incubated for 1 hour
at 37˚C. Wells were washed and then incubated for 15 minutes at 37˚C with 1 μg/ml rabbit
anti-human-MPO antibody (Dako) in PBS supplemented with 0.1% BSA. Following an
additional washing step, anti-MPO-antibodies were detected by incubating wells with
0.1 μg/ml horseradish peroxidase (HRP)-conjugated goat antibodies against rabbit IgG
(Santa Cruz) for 15 minutes at 37˚C. After washing, HRP-activity was detected using
ABTS solution (Life Technologies). NETs were isolated from activated neutrophils as pre-
viously described [26] and used as a positive control.
Statistical analysis
We compared the concentration of ceDNA, circulating nucleosomes, and NETs in patient plasma
by type of the index VTE using a nonparametric test for trend across ordered groups according
to Cuzick [27]. For associations between the concentration of ceDNA and death, an ordinary
Cox-regression with robust standard errors was calculated. For PE-related, non-PE-related, can-
cer-related, and non-cancer-related death, a competing risk regression was performed accounting
for other causes of death as a competing event, according to the method of Fine and Gray [27].
We adjusted the models for risk factors that had been previously shown to be associated with the
outcomes [28]. The method yields subhazard ratios (SHR) with corresponding 95% confidence
intervals and p-values for the failure event of primary interest. VTE recurrence was adjusted for
age, gender, cancer, provoked index VTE, and periods of oral or parenteral anticoagulation as a
time-varying covariate. Mortality was adjusted for age, gender, overt PE, cancer, immobilization,
heart failure, chronic lung disease, us-CRP, and periods of anticoagulation as a time-varying
covariate. Cancer- and non-cancer-related mortality was adjusted for age, gender, overt PE, im-
mobilization, chronic lung disease, us-CRP, and periods of anticoagulation as a time-varying
covariate. Due to low number of events, PE- and non-PE-related mortality was only adjusted for
age, overt PE, cancer, us-CRP, and periods of anticoagulation as a time-varying covariate. The dis-
criminative ability of ceDNA for VTE recurrence and mortality was assessed by Harrell’s C con-
cordance statistic. The prognostic ability for 3-month mortality was assessed by the area under the
ROC curve (AUC). The added predictive ability of ceDNA combined with other biomarkers was
assessed by the integrated discrimination improvement (IDI) index, which is based on a logistic
model and was calculated by the method of Pencina et al [28]. All analyses were done using Stata
14 (Stata Corporation, College Station, Texas).
Results
Circulating extracellular DNA indicates the extent of VTE in patients
We used a fluorescent probe to quantify ceDNA in citrated plasma from patients of the
SWITCO65+ study. The cohort enrolled patients aged 65 years or older with acute,
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symptomatic VTE (Table 1). Our study focuses on patients with a first acute VTE event and
therefore excluded patients with prior VTE (S1 Fig). We analyzed 611 VTE patients includ-
ing 51 patients with distal DVT only, 133 patients with proximal DVT, and 427 patients
with PE (Table 1). The levels of ceDNA increased with the extent of VTE categorized as iso-
lated distal DVT, proximal DVT, and PE (Fig 1A). To investigate the potential origin of
ceDNA, we correlated the levels of ceDNA, with levels of circulating nucleosomes, and
NETs. We used an antibody against an epitope on the complex of DNA, histone H2A, and
histone H2B to immunoabsorb and quantify nucleosomes. NETs, which are characterized
as chromatin fibers containing enzymes from neutrophil granules [12], were quantified by
detection of the complex of DNA, histones, and myeloperoxidase. We observed a strong
correlation of ceDNA and circulating nucleosomes (Spearman r = 0.656, p < 0.001), indi-
cating that ceDNA in VTE patients is circulating in part as nucleosomes. Levels of ceDNA
and NETs did not correlate (Spearman r = 0.057, p = 0.159), suggesting that NETs are not a
major component of ceDNA in VTE patients. In line with these results, levels of ceDNA
(z-statistics: 4.26; p < 0.001) and circulating nucleosomes (3.48; p = 0.001), but not NETs
(1.72; p = 0.086) correlated significantly with the extent of VTE (Fig 1B and Fig 1C).
We previously observed that high concentrations of anticoagulants, in particular hepa-
rins, disintegrate NETs in vitro [29]. We analyzed the effect of anticoagulation (AC; paren-
teral or Vitamin K antagonist) on ceDNA levels in acute VTE patients. AC was given to
362 patients more than one day before blood sampling, to 139 patients one day before blood
sampling, to 105 patients after blood samples, while 5 patients did not receive AC. We ob-
served no significant association between ceDNA and timing of AC start (Kruskal-Wallis
Fig 1. Association of ceDNA, circulating nucleosomes, and NETs with VTE extent. (A) CeDNA and (B) circulating nucleosomes in plasma correlated with the extent
of VTE. (C) Plasma levels of the NET-specific biomarker, DNA-histone-MPO complexes, did not significantly correlate with VTE extent. Extent of acute VTE was
categorized as isolated distal DVT only (n = 51), proximal DVT ± distal DVT (n = 133), and PE ± DVT (n = 427). All VTE (n = 611). FU: Fluorescent units; OD: Optical
density. Data is shown as median ± inter-quartile range. P-values were calculated using a nonparametric test for trend across ordered groups.
https://doi.org/10.1371/journal.pone.0191150.g001
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test; p = 0.24), suggesting that AC therapy has no major effect of ceDNA levels. These data
furthermore support that NETs are not a major source of ceDNA in acute VTE patients.
Circulating extracellular DNA predicts mortality after acute VTE
We analyzed a possible association of ceDNA with the clinical outcome following acute VTE.
The median follow-up time was 29.7 months (IQ-range: 18.2–40.7). We trichotomized VTE
patients based on their concentration of ceDNA at the time of acute VTE, choosing the 75th
percentile, and 25th percentile as pre-specified cut-off values. Seventy patients suffered recur-
rent VTE during follow-up. We did not observe an association of increased ceDNA levels with
VTE recurrence (Fig 2A). Analyzing continuous rather than trichotomized ceDNA levels
showed similar results (Table 2). 129 patients died during follow-up. Analysis of trichotomized
(Fig 2B) and continuous data (Table 2) revealed that elevated levels of ceDNA at acute VTE
strongly increase the risk of mortality. Forty-one of 611 patients died within 3 months after
acute VTE and calculation of hazard ratios (HR) and adjusting for several confounders re-
vealed that ceDNA was significantly associated with an approximately 2.5-fold increase in risk
of death (HR: 2.57, 95%-CI 1.59–4.15; Table 3). The cause of death was related to PE in 9
patients (S1 Table). Elevated levels of ceDNA were associated with an approximately 3.5-fold
increased risk of fatal PE (HR: 3.68; 95%-CI 1.70–7.94) and 2-fold increased risk of non-PE-
related causes of death (HR: 1.85, 95%-CI 1.27–2.71; Table 3).
Levels of ceDNA are elevated in various conditions [5]. We analyzed whether comorbid
conditions in our VTE patients are associated with increased levels of ceDNA. Adjusting for
age, sex, and all other comorbidities in a multivariate linear regression revealed that an accom-
panying or preceding severe infection or sepsis, but not cancer, was independently associated
Fig 2. Association of ceDNA with the outcome following acute VTE. Kaplan-Meier-curves show the cumulative incidence of (A) VTE
recurrence and (B) mortality. Patients were grouped according to the concentration of ceDNA at the time of acute VTE into high levels
(4th quartile, red line), medium levels (2nd-3rd quartile, grey line), and low levels (1st quartile, black line). VTE patients with high ceDNA
have an increased risk of mortality, but not VTE recurrence. P-values were calculated using a logrank test.
https://doi.org/10.1371/journal.pone.0191150.g002
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with increased levels of ceDNA in VTE (Table 4). In line with these results, the association of
ceDNA with cancer-related mortality (HR: 2.43; 95%-CI 1.46–4.03) and non-cancer-related
mortality (HR: 2.26; 95%-CI 1.27–4.01) was comparable (Table 3).
Circulating extracellular DNA is associated with markers of acute
inflammation
We questioned whether ceDNA is associated with other established markers of thrombosis and
inflammation. We used platelet counts and levels of the fibrin degradation product D-dimer as
surrogate markers for thrombosis. Levels of ultra-sensitive C-reactive protein (us-CRP) and white
blood cell counts were used as biomarkers of acute inflammation. We observed no or a weak cor-
relation of ceDNA with platelets (Spearman r: 0.05; p = 0.252) and D-dimer (r: 0.08; p = 0.041),
respectively. CeDNA did strongly correlate with us-CRP (r: 0.37; p< 0.001) and leukocytes (r:
0.23; p< 0.001), suggesting that increased levels of ceDNA are associated with acute inflamma-
tion in VTE patients. A statistical comparison of biomarkers revealed that ceDNA and us-CRP,
but not leukocytes, platelets or d-dimer, significantly predicted death following acute VTE (Fig
3). Furthermore, ceDNA was associated with an increased risk of mortality independently of
Table 2. Association of ceDNA with VTE recurrence and mortality during follow-up.
n C-statistics 95% CI p-value
VTE recurrence
Up to 3 months 4 0.34 0.18–0.50 0.056
Up to 12 months 32 0.45 0.35–0.54 0.284
Up to 24 months 60 0.44 0.37–0.52 0.133
Up to 36 months 70 0.45 0.38–0.52 0.144
Mortality
Up to 3 months 41 0.71 0.61–0.80 < 0.001
Up to 12 months 76 0.65 0.58–0.72 < 0.001
Up to 24 months 114 0.61 0.55–0.66 < 0.001
Up to 36 months 129 0.60 0.55–0.65 < 0.001
CeDNA was not significantly associated with VTE recurrence, but strongly associated with all-cause mortality.
CeDNA was used as continuous variable; n: number of events. 95% CI, 95% confidence interval. P-values were
calculated for the C-statistics. A C-statistics value of 0.5 indicates no predictive value (null hypothesis).
https://doi.org/10.1371/journal.pone.0191150.t002
Table 3. Association of log-transformed ceDNA with 3-month mortality.
crude adjusted
n HR or SHR 95% CI p-value HR or SHR 95% CI p-value
All-cause mortality 41 2.65 1.79–3.92 < 0.001 2.57 1.59–4.15 < 0.001
PE-related death 9 3.62 2.10–6.23 < 0.001 3.68 1.70–7.94 0.001
Non-PE-related death 32 2.03 1.43–2.90 < 0.001 1.85 1.27–2.71 0.002
Cancer-related death 15 2.36 1.54–3.60 < 0.001 2.43 1.46–4.03 0.001
Non-cancer-related death 26 2.50 1.56–4.01 < 0.001 2.26 1.27–4.01 0.005
Crude and adjusted subhazard ratios (SHR) with 95% confidence intervals, and corresponding p-values. In case of overall mortality, the hazard ratio (HR) is shown (no
competing risk). HR/SHRs are expressed per one log-unit increase in ceDNA. Adjustment was done for age, gender, overt PE, cancer, immobilization, heart failure,
chronic lung disease, periods of anticoagulation, and us-CRP as a time-varying covariate. Due to low number of events, PE- and non-PE-related mortality was only
adjusted for age, overt PE, and periods of anticoagulation as a time-varying covariate. Cancer- and non-cancer-related mortality was adjusted for age, gender, overt PE,
immobilization, chronic lung disease, periods of anticoagulation, and us-CRP as a time-varying covariate.
https://doi.org/10.1371/journal.pone.0191150.t003
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other biomarkers tested, and the combination of ceDNA and us-CRP predicted mortality more
accurately than each marker alone (S2 Table). In conclusion, our study shows that ceDNA is a
strong and independent predictor of mortality following acute VTE.
Discussion
In 1973, Davis and colleagues first identified ceDNA in plasma from patients with PE [4]. A
number of subsequent studies confirmed the increased levels of ceDNA in DVT and PE pa-
tients compared to healthy controls [5]. CeDNA exists in different forms including mitochon-
drial DNA (mtDNA), nuclear DNA (nDNA), nucleosomes, consisting of nDNA in complex
with histones, as well as NETs [5]. Current methods detecting ceDNA employ DNA-specific
fluorescent dyes, qPCR, and ELISA. Quantification of nDNA- and mtDNA-specific DNA se-
quences in plasma from 74 PE patients revealed that patients with massive PE have higher
ceDNA levels than patients with sub-massive PE [30]. Higher levels of nDNA and mtDNA fur-
thermore correlate with increased risk for mortality within 15 days [30]. Similarly, levels of cir-
culating nucleosomes and ceDNA are increased in patients with DVT when compared to
patients with clinical suspicion of DVT, but in whom DVT was excluded [13, 14].
We analyzed the association of ceDNA in plasma with the extent and outcome of acute
VTE. Our study focused on the detection of ceDNA by fluorescent dyes. This method is auto-
matable, cost-effective, and provides rapid results and thus may be used in a clinical diagnostic
setting in future. We observed that levels of ceDNA strongly correlated with VTE extent and
predicted mortality, but not VTE recurrence. Furthermore, we identified a strong association
of ceDNA with markers of laboratory markers of acute inflammation. Our study focuses on
acute VTE in elderly patients, the epidemiologically most relevant age group [3]. We have ana-
lyzed the levels of ceDNA in more than 600 patients. To our knowledge, our study is the largest
analysis of ceDNA in patients to date. The evaluation of a large prospective cohort identified
that non-infectious comorbidities including cancer do not independently increase ceDNA lev-
els in acute VTE. This suggests that the increase of ceDNA levels is mainly a consequence of
acute VTE. The source of ceDNA in VTE patients is unknown. NETs are abundantly present
in thrombi from VTE patients [31]. Furthermore, in animal models, the formation of NETs
Table 4. Association of ceDNA with comorbidities.
crude adjusted
n CR 95% CI p-value AR 95% CI p-value
Severe infection/sepsis 52 1.43 1.19–1.72 < 0.001 1.34 1.11–1.63 0.003
Active cancer 127 1.18 1.04–1.34 0.011 1.09 0.95–1.24 0.234
Arterial hypertension 388 1.06 0.95–1.18 0.274 1.10 0.98–1.23 0.114
Diabetes mellitus 97 1.02 0.89–1.18 0.744 0.98 0.84–1.14 0.785
Chronic lung disease 80 0.97 0.83–1.13 0.678 0.90 0.77–1.06 0.211
Chronic or acute heart failure 78 1.03 0.88–1.20 0.722 1.00 0.85–1.18 0.981
Inflammatory bowel disease 18 1.04 0.77–1.41 0.803 0.96 0.70–1.31 0.788
Acute rheumatic disease 20 0.99 0.74–1.32 0.935 1.02 0.76–1.37 0.886
Major surgery 106 1.16 1.01–1.33 0.036 0.99 0.85–1.17 0.945
Renal failure 35 1.11 0.89–1.39 0.351 1.10 0.87–1.40 0.408
Crude and adjusted robust linear regression of log-transformed ceDNA on comorbidities. Adjustment was done for age, gender, severe infection/sepsis, active cancer,
arterial hypertension, diabetes mellitus, chronic lung disease, chronic or acute heart failure, inflammatory bowel disease, acute rheumatic disease, major surgery, renal
failure (GFR < 30 ml/min), estrogen therapy, immobilization, history of major bleeding, anemia, concomitant antiplatelet therapy, and anticoagulation prior to index
VTE. Coefficients were back-transformed by exponentiation yielding ratios. CR: crude ratio; AR: adjusted ratio.
https://doi.org/10.1371/journal.pone.0191150.t004
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during thrombosis timely coincides with an elevation in ceDNA [29]. However, NETs levels
in plasma neither correlated with ceDNA nor with VTE extent, suggesting that NETs are not
the main source of ceDNA in VTE patients. Therefore, it is conceivable that ceDNA derives
from injured tissue, which is damaged due to the thrombotic occlusion of supplying blood ves-
sels. Indeed, ceDNA levels correlate with markers of cell injury and size of ischemic lesions in
several cardiovascular and thromboembolic diseases, including myocardial infarction, stroke,
and venous thromboembolism [5]. DNA, histones, or other damage-associated molecular pat-
terns (DAMPs) may initiate an inflammatory response via activating pattern-recognition re-
ceptors on immune cells [32]. In line with this hypothesis, we observed a strong correlation of
ceDNA with markers of acute inflammation, namely us-CRP and circulating leukocytes. In-
creased levels of ceDNA may indicate the degree of systemic inflammation, which is associated
with shortened survival after a VTE event. In conclusion, ceDNA may help identifying VTE
patients with a poor prognosis and improve the clinical management of VTE in the future.
Fig 3. Comparison of the ceDNA to laboratory markers of inflammation and thrombosis for the prediction of
3-month-mortality. Area under the curve (AUC) from ROC analysis of ceDNA, us-CRP, leukocyte count, D-dimer,
platelet count shows ceDNA and usCRP to be strong predictors of 3-months mortality following acute VTE.
https://doi.org/10.1371/journal.pone.0191150.g003
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